Article
Preliminary Safety and Efficacy Results Observed for AMG 160 in mCRPC
Rating:
0.0
Views:
91
Likes:
1
Library:
1
The bispecific T‐cell engager, AMG 160, demonstrated a manageable safety profile and preliminary evidence of efficacy in heavily pretreated patients with metastatic castration-resistant prostate cancer in a 2-part, phase 1
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value